1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.
    PLEASE HELP

Piracetam for dementia or cognitive impairment

Piracetam for dementia or cognitive impairment

  1. BitterSweet
    Objectives

    To determine the clinical efficacy of piracetam for features of dementia (classified into the major subtypes: vascular, Alzheimer's disease or mixed vascular and Alzheimer's disease, or unclassified dementia) or cognitive impairment not fulfilling diagnostic criteria for dementia.

    Search methods

    We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register on 4 December 2011 using the terms: piracetam, nootropic, "2-Oxo-1-pyrrolidine", Lucetam, Nootropil, Breinox. We identified another review by employees and consultants of the manufacturing company, UCB Pharma (Waegemans 2002) which included data from unpublished studies not made available to Cochrane review authors.

    Selection criteria

    All unconfounded, randomized, double-blind trials in which treatment with piracetam was administered for more than a day and compared with placebo in people with dementia of Alzheimer type, vascular dementia, or mixed vascular and Alzheimer's disease, or unclassified dementia, or cognitive impairment not fulfilling diagnostic criteria for dementia.

    Data collection and analysis

    Two review authors independently extracted data from studies fulfilling the inclusion criteria. We used Intention-to-treat analysis where feasible and pooled studies if appropriate. We planned to perform sensitivity analyses to determine if studies performing poorly on quality criteria affected results. The pharmaceutical company marketing piracetam did not release the results of several unpublished trials.

    Main results

    There were 24 included studies with 11959 participants in total. Many studies were of cross-over design and first-phase data were unavailable, or could not be extracted. Global impression of change (GIC) was the only outcome for which pooling of data was possible, involving only four studies. There was evidence of heterogeneity in the results, Chi2 test = 19.17 (df = 3, P < 0.001). The odds ratio (OR) for improvement in the piracetam group compared with placebo was 3.43 (95% confidence interval (CI) 2.32 to 5.07). Using a fixed-effect model, the OR for improvement with piracetam compared with placebo was 3.55 (95% CI 2.45 to 5.16). This estimate was derived from completers rather than from an intention-to-treat analysis as relevant data could not be extracted from the reports.

    In the limited data available, no significant differences were found between treatment and placebo groups for cognition (immediate memory, visuospatial, Mini Mental Status Examination (MMSE), delayed memory or speech) for dependency, or for depression. The large volume of unpublished and untraceable data not available to the review authors raises the possibility of publication bias.

    Authors' conclusions

    Published evidence does not support the use of piracetam in the treatment of people with dementia or cognitive impairment. Although effects were found on global impression of change, no benefit was shown by any of the more specific measures of cognitive function. The evidence indicates a need for further evaluation of piracetam.


    Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD001011. DOI: 10.1002/14651858.CD001011.